Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Net Cash Flow (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Net Cash Flow for 5 consecutive years, with $104.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 466.0% to $104.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $151.2 million through Dec 2025, up 1262.27% year-over-year, with the annual reading at $151.2 million for FY2025, 1262.27% up from the prior year.
  • Net Cash Flow hit $104.3 million in Q4 2025 for Krystal Biotech, up from $39.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $135.1 million in Q2 2023 to a low of -$72.6 million in Q2 2021.
  • Historically, Net Cash Flow has averaged $11.4 million across 5 years, with a median of -$13.8 million in 2023.
  • Biggest YoY gain for Net Cash Flow was 466.0% in 2025; the steepest drop was 7486.15% in 2025.
  • Year by year, Net Cash Flow stood at $54.6 million in 2021, then tumbled by 144.79% to -$24.5 million in 2022, then surged by 39.62% to -$14.8 million in 2023, then plummeted by 92.97% to -$28.5 million in 2024, then soared by 466.0% to $104.3 million in 2025.
  • Business Quant data shows Net Cash Flow for KRYS at $104.3 million in Q4 2025, $39.1 million in Q3 2025, and $44.0 million in Q2 2025.